select a format

Single User License
USD 3500 INR 227570
Site License
USD 7000 INR 455140
Corporate User License
USD 10500 INR 682710

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Surface Protein gp120-Pipeline Review, H2 2016

Surface Protein gp120-Pipeline Review, H2 2016


  • Products Id :- GMDHC0508TDB
  • |
  • Pages: 75
  • |
  • August 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Surface Protein gp120-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Surface Protein gp120-Pipeline Review, H2 2016', provides in depth analysis on Surface Protein gp120 targeted pipeline therapeutics.

The report provides comprehensive information on the Surface Protein gp120, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Surface Protein gp120 targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Surface Protein gp120

The report reviews Surface Protein gp120 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Surface Protein gp120 targeted therapeutics and enlists all their major and minor projects

The report assesses Surface Protein gp120 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Surface Protein gp120 targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Surface Protein gp120

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Surface Protein gp120 development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Surface Protein gp120 Overview 8

Therapeutics Development 9

Surface Protein gp120-Products under Development by Stage of Development 9

Surface Protein gp120-Products under Development by Therapy Area 10

Surface Protein gp120-Products under Development by Indication 11

Surface Protein gp120-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Surface Protein gp120-Products under Development by Companies 14

Surface Protein gp120-Products under Development by Universities/Institutes 16

Surface Protein gp120-Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Surface Protein gp120-Companies Involved in Therapeutics Development 24

GlaxoSmithKline Plc 24

Osel, Inc. 25

Sanofi Pasteur SA 26

TeneoBio Inc 27

United Biomedical, Inc. 28

ViiV Healthcare Limited 29

Surface Protein gp120-Drug Profiles 30

Abzentek-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

AIDSVAX B/B + ALVAC-HIV vCP1521-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Biologic for Infectious Disease-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

BMD-101-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

BMD-104-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

BMS-585248-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DS-003-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

fostemsavir tromethamine-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

HIV [strains C1086 + TV1] (bivalent) vaccine-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

HIV vaccine-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HIV vaccine-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

HIV vaccine 1-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

HIV-1 vaccine-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

HNG-156-Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

M-48U1-Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Monoclonal Antibodies to Inhibit GP120 for HIV-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Monoclonal Antibodies to Inhibit Gp120 for HIV-1 Infection-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Monoclonal Antibodies to Target GP120 and GP41 for HIV-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Monoclonal Antibody to Inhibit Glycoprotein 120 for HIV-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Recombinant Peptide to Inhibit gp120 for HIV-1-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Recombinant Protein to Target gp120 for HIV-1 Infections-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

VCP-2438-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

VRC-01LS-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Surface Protein gp120-Dormant Projects 59

Surface Protein gp120-Discontinued Products 62

Surface Protein gp120-Featured News & Press Releases 63

May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa 63

Jan 07, 2016: National Institutes of Health Initiates Phase 1 Trial of VRC01LS Anti-HIV Therapeutic Antibody Using Xencor's Xtend Fc Technology 64

Dec 02, 2015: Abzyme Research Foundation's Inaugural ENDHIV BALL Launches USD 3 Million Fund for New Therapeutic HIV Vaccine Trial 64

Jul 21, 2015: Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor for Heavily Treatment-Experienced Patients 65

Jul 08, 2015: Scripps research-designed drug candidate significantly reduces HIV reactivation rate 66

Feb 25, 2015: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation 67

Oct 03, 2014: Bristol-Myers Squibb Presents Data of BMS-663068 at IDWeek 2014 Showcasing Continued Innovation in Virology 68

Jul 30, 2014: Dissolvable fabric loaded with medicine might offer faster protection against HIV 69

Mar 05, 2014: Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients 70

May 06, 2013: Duke Researchers Report Additional Information From Phase III HIV Vaccine Trial In Thailand 71

Dec 06, 2012: Vaginal microbicide gel may offer a promising strategy for prevention and protection against HIV transmission 72

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by GlaxoSmithKline Plc, H2 2016 24

Pipeline by Osel, Inc., H2 2016 25

Pipeline by Sanofi Pasteur SA, H2 2016 26

Pipeline by TeneoBio Inc, H2 2016 27

Pipeline by United Biomedical, Inc., H2 2016 28

Pipeline by ViiV Healthcare Limited, H2 2016 29

Dormant Projects, H2 2016 59

Dormant Projects (Contd..1), H2 2016 60

Dormant Projects (Contd..2), H2 2016 61

Discontinued Products, H2 2016 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

GlaxoSmithKline Plc

Osel, Inc.

Sanofi Pasteur SA

TeneoBio Inc

United Biomedical, Inc.

ViiV Healthcare Limited

Surface Protein gp120 Therapeutic Products under Development, Key Players in Surface Protein gp120 Therapeutics, Surface Protein gp120 Pipeline Overview, Surface Protein gp120 Pipeline, Surface Protein gp120 Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com